A systematic review updated through December 2025 confirms that SARS-CoV-2 infection can trigger adrenal insufficiency in individuals with no prior history of adrenal disease, raising concerns for Thailand residents navigating persistent post-infection health complications. The condition—marked by inadequate cortisol production—can escalate to life-threatening crises if left undiagnosed, particularly among the estimated 28-52% of COVID-19 survivors experiencing prolonged symptoms.
Why This Matters
• Treatment is available: Patients diagnosed with adrenal insufficiency require daily glucocorticoid replacement therapy (hydrocortisone or prednisolone), with adjusted dosing during illness to prevent acute crises.
• Detection gap persists: Symptoms like chronic fatigue, dizziness, nausea, and joint pain overlap with common Long COVID complaints, making diagnosis challenging without targeted hormone testing.
• Thailand-specific data: A July 2024 study of 41 severe COVID-19 pneumonia survivors in Thailand found 27% developed hypocortisolism, with 54.5% reporting chronic exhaustion and 45.5% requiring lifelong hormone replacement.
• Risk extends beyond acute phase: Cases have appeared weeks to months after initial recovery, suggesting ongoing surveillance is critical for post-COVID clinic populations.
How the Virus Attacks Hormone Production
Research has identified multiple mechanisms through which coronavirus disrupts the hypothalamic-pituitary-adrenal (HPA) axis. Receptors for ACE2—the protein SARS-CoV-2 uses to enter cells—are abundant in the adrenal glands, pituitary gland, and hypothalamus. Autopsy studies globally have documented tissue necrosis, microthrombi formation, hemorrhaging, and inflammatory cell infiltration in adrenal tissue of COVID-19 victims.
Two distinct pathways emerge from research:
Central Adrenal Insufficiency: The virus triggers inflammation in the pituitary gland (viral hypophysitis) or disrupts hypothalamic function, reducing ACTH hormone release. This secondary form accounted for 10 of 11 hypocortisolism cases in the Thailand cohort—patients whose upstream command centers failed rather than the adrenal glands themselves.
Primary Adrenal Failure: In severe COVID-19, hypercoagulable states increase risk of bilateral adrenal hemorrhage or infarction. This direct organ destruction requires immediate intervention, as both glands lose cortisol-producing capacity simultaneously.
A third complicating factor involves critical illness-related corticosteroid insufficiency (CIRCI), where the body cannot meet surging cortisol demands during acute infection despite intact organs. High-dose corticosteroid treatment during hospitalization may also suppress HPA axis function long-term or unmask pre-existing adrenal weakness.
Impact on Thai Residents and Expats
For individuals managing Long COVID in Thailand—where Omicron-wave studies show 52.59% experienced lingering symptoms at 3 months—the adrenal insufficiency risk adds complexity to care. Fatigue, the most common Long COVID complaint, could signal hormone deficiency rather than post-viral syndrome alone. Published data on nationwide prevalence in Thailand remains limited, with physicians relying primarily on case reports and small cohort studies.
Key diagnostic challenges include:
• Symptom overlap: Weakness, dizziness, gastrointestinal upset, and muscle pain appear in both Long COVID and adrenal insufficiency, delaying hormone testing.
• Varied diagnostic thresholds: Small Thai observational studies use inconsistent cortisol cutoff values, making prevalence estimates unreliable.
• Delayed onset: Some patients develop hypocortisolism months post-recovery, after discharge from post-COVID monitoring programs.
Researchers recommend hypocortisolism screening for all severe COVID-19 pneumonia survivors, regardless of whether fatigue symptoms are present. Morning cortisol testing paired with ACTH stimulation tests can confirm diagnosis within clinical settings accessible across Bangkok, Chiang Mai, and provincial hospitals.
Lifesaving Treatment Protocols
Once diagnosed, adrenal insufficiency management centers on hormone replacement therapy that mimics natural cortisol rhythms. Standard treatment protocols used by Thai endocrinologists include:
Standard Dosing:
• Hydrocortisone 15-25 mg daily (split into 2-3 doses)
• Prednisolone 5-15 mg daily (single morning dose)
• Fludrocortisone 50-200 mcg daily if mineralocorticoid deficiency exists
Sick Day Rules (Critical During COVID Reinfection):When fever, respiratory infection, or vomiting occurs, patients must double or triple glucocorticoid doses to prevent adrenal crisis. For hydrocortisone users, the protocol shifts to 20 mg every 6 hours (80 mg daily). Prednisolone users at baseline 5-15 mg should take 10 mg every 12 hours.
Emergency Intervention:Patients deteriorating despite oral dose increases require 100 mg intravenous hydrocortisone bolus followed by 200 mg/24-hour continuous infusion or 50 mg every 6 hours intramuscularly. Home emergency injection kits (Solu-Cortef) allow self-administration before hospital transport—essential given Thailand's traffic congestion and rural access barriers.
Medical alert cards and wristbands identifying adrenal insufficiency status help emergency responders avoid fatal delays. Thailand expats should ensure their insurance covers endocrinology consultations and carry sufficient glucocorticoid supplies when traveling domestically, as shortages periodically affect provincial pharmacies.
Broader Long COVID Landscape
Adrenal dysfunction represents one tile in Long COVID's mosaic of complications affecting multiple organ systems. Recent 2025-2026 research catalogues the condition's reach:
Neurological: A May 2026 Yale University study and June 2026 NIH research confirmed that autoantibodies in some Long COVID patients attack brain and nerve tissue, explaining brain fog, headaches, numbness, and autonomic dysfunction. March 2026 findings specifically linked Omicron infections to persistent cognitive impairment and paresthesia.
Cardiovascular: June 2026 data shows sustained vascular abnormalities in Long COVID patients, predominantly hypertension. Risks for myocarditis, pulmonary embolism, and heart failure remain elevated. Chest tightness, palpitations, and irregular heartbeats affect significant subsets.
Hematologic: SARS-CoV-2 reprograms blood-forming progenitor cells for months post-infection, with molecular changes persisting in stem cell populations. Community COVID-19 surges correlate with measurable increases in pulmonary embolism cases three weeks later.
Musculoskeletal: Muscle pain, weakness, and post-exertion malaise (PEM) affect approximately 40% of young nursing students with Long COVID in recent cohorts, indicating substantial burden among working-age adults.
Endocrine: Beyond adrenal insufficiency, Long COVID disrupts cortisol, testosterone, and estradiol levels. Pediatric patients show abnormal lipid metabolism and BMI changes. Reproductive health consequences include menstrual irregularities, endometriosis flares, sexual dysfunction, and reduced sperm quality.
Gastrointestinal: New-onset food intolerances, alternating diarrhea and constipation, and reduced appetite emerge in subsets of patients.
Pregnancy Outcomes: Long COVID correlates with miscarriage, preterm birth, preeclampsia, and maternal mortality—critical information for Thailand's childbearing-age population.
Global incidence data through September 2024 estimates 5.3-7.6% of U.S. adults currently experience Long COVID, with worldwide rates around 29% among non-hospitalized cases. Female sex, advanced age, obesity, multiple initial symptoms, and pre-existing conditions increase risk. Crucially, infection severity no longer predicts Long COVID development—mild cases progress to chronic symptoms as frequently as severe ones.
Vaccination before infection reduces Long COVID risk by 41% according to 2025 meta-analyses, though post-infection vaccination shows minimal benefit for existing symptoms. Reinfection compounds risk, with each subsequent COVID-19 episode raising odds of developing or worsening Long COVID manifestations.
Regional Surveillance and Next Steps
South Korea recently reported sharp increases in coronavirus detection rates through national respiratory surveillance, signaling potential resurgence threats that could reach Southeast Asia. For Thailand—where porous borders, tourism rebound, and variable vaccination coverage create vulnerability—tracking Long COVID complications like adrenal insufficiency requires infrastructure investment.
The Thailand Department of Medical Sciences has yet to establish centralized reporting for post-COVID endocrine dysfunction, leaving physicians reliant on case reports and small cohort studies. Expanding post-COVID clinics to include routine hormonal screening, establishing diagnostic thresholds for Thai populations, and training primary care doctors to recognize adrenal crisis symptoms could prevent avoidable deaths.
For residents and expats, maintaining vigilance around unexplained fatigue, especially following COVID-19 hospitalization, warrants endocrinology consultation. Private hospitals in Bangkok including Bumrungrad, Samitivej, and Bangkok Hospital offer comprehensive hormone panels and ACTH stimulation testing. Provincial hubs like Chiang Mai Ram and Phuket's Bangkok Hospital Siriroj provide similar capabilities.
Those diagnosed should request multilingual sick-day protocol cards, verify emergency injection availability at their nearest hospital, and brief household members on crisis recognition. Thailand's humid climate increases dehydration risk during febrile illnesses—a particular hazard for adrenal insufficiency patients whose cortisol deficit impairs sodium retention.
As COVID-19 transitions to endemic circulation with periodic variant-driven waves, understanding its capacity to reprogram endocrine function months after "recovery" becomes essential for long-term health planning. The adrenal insufficiency link, now supported by systematic review evidence and Thai clinical data, requires sustained medical attention as COVID-19 transitions to endemic patterns. Coronavirus consequences extend far beyond respiratory symptoms—demanding ongoing clinical vigilance even as acute pandemic measures fade.
